Universal Ibogaine Inc IBOGF

Ibogaine to treat the root of addiction.

[Oldschool2022]

As it stands, Universal Ibogaine is the only public company focused on medicalizing ibogaine as a drug development platform to treat the root of addiction and its concurrent disorders.

With clinical data already in hand to inform clinical trials and a revenue generating facility acquired, the company is set to develop a wide range of treatments and expand to a global network of clinics. All this coupled with a favorable early-stage valuation makes Universal Ibogaine an enticing company for investors to watch.

A summary of Universal Ibogaine’s investment thesis:

• The company offers an opportunity to help tackle the scourge of addiction by presenting an ethical, medically supervised, and regulatory sanctioned channel to participate in the psychedelics space
• The company’s ibogaine “biotech” play is supported by real world data demonstrating safety and efficacy through the successful track record of the Clear Sky Recovery protocol
• Universal Ibogaine represents a commercialization and monetization opportunity in a massive, severely underserved, therapeutic area: addiction, mental/behavioral health and overall nervous system (CNS) disorders
• The company presents an opportunity to capture the biotech upside with the stability of growing near-term revenue from expansion of clinic operations
• Universal Ibogaine’s valuation is favourable compared with companies in the (psychedelic) space as they are in the ground level/ pre-transformative growth stage
•